Top Story

Apatorsen combination improves survival in metastatic bladder cancer

October 26, 2016

The phase 2 Borealis-2 trial designed to evaluate apatorsen in combination with docetaxel for the treatment of metastatic bladder cancer showed positive OS results, according to the drug’s manufacturer.

Researchers randomly assigned 200 patients with metastatic bladder cancer who had disease progression following first-line platinum-based chemotherapy to receive either apatorsen (OncoGenex) in combination with docetaxel treatment or docetaxel alone.

Olaparib maintenance prolongs PFS in women with BRCA–mutated ovarian cancer

October 26, 2016
The phase 3 SOLO-2 trial designed to evaluate the efficacy of olaparib for the maintenance treatment of platinum-sensitive relapsed, BRCAmutated ovarian cancer…
In the Journals

Cutaneous malignancies may be rare complication of hidradenitis suppurativa

October 26, 2016
Women with chronic hidradenitis suppurativa experienced rare complications of cutaneous squamous cell carcinoma of the vulvar, perianal and perineal regions, according…
Meeting News

Photodynamic therapy, stents increase survival for extrahepatic cholangiocarcinoma

October 26, 2016
The use of photodynamic therapy with stents was safe and increased survival among patients with unresectable extrahepatic cholangiocarcinoma vs. stents alone, per…
In the Journals Plus

PSA screening practices appear unchanged since USPSTF recommendation

October 26, 2016
PSA ordering and referral practices have not significantly changed since the U.S. Preventive Services Task Force issued recommendations against the routine use of PSA…
More News Headlines »
CME Video

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-Line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Meeting News Coverage

VIDEO: Combination therapy with PD-L1, PARP inhibitors appears effective in patients with ovarian, breast cancer

September 8, 2016
More »

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Current Issues
View the Current Issue
HemOnc Today